TEVA - Teva Pharma Industries Ltd ADR
Exchange: USA Stocks • Country: Israel • Currency: USD • Type: Common Stock • ISIN: US8816242098
Generic Medicines, Specialty Medicines, Biopharmaceuticals
Teva Pharmaceutical Industries Limited is a global leader in the development, manufacturing, and distribution of a wide range of pharmaceutical products, including generic medicines, specialty medicines, and biopharmaceuticals. The company operates in over 60 countries, with a strong presence in North America, Europe, Israel, and other international markets.
Teva's generic medicine portfolio is extensive, offering a variety of dosage forms such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. The company specializes in producing high-quality, affordable generic versions of branded medicines, including sterile products, hormones, high-potency drugs, and cytotoxic substances. Additionally, Teva offers generic products with medical devices and combination products, catering to diverse patient needs.
The company has a strong focus on three key therapeutic areas: central nervous system (CNS), respiratory, and oncology. In CNS, Teva offers treatments for conditions such as multiple sclerosis, migraine, and neurodegenerative disorders. In respiratory, the company provides inhalation products for asthma and chronic obstructive pulmonary disease (COPD). In oncology, Teva offers injectable treatments for various types of cancer, including chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Teva also provides active pharmaceutical ingredients (APIs) and contract manufacturing services to other pharmaceutical companies. Its out-licensing platform offers a portfolio of products to partners, enabling them to expand their offerings. The company has collaboration agreements with several partners, including MedinCell, Sanofi, Alvotech, and Biolojic Design Ltd., to develop and commercialize new products.
In addition to its prescription medicines, Teva offers a range of over-the-counter (OTC) products under various brand names, including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA. These products cater to everyday healthcare needs, such as skin care, pain relief, and respiratory health.
Founded in 1901, Teva Pharmaceutical Industries Limited is headquartered in Tel Aviv, Israel, and has a rich history of innovation and growth. Today, the company is a leading global pharmaceutical player, committed to improving healthcare outcomes and making quality medicines accessible to patients around the world.
Drawdown (Underwater) Chart
![Drawdown / Underwater Chart for TEVA - Teva Pharma Industries Ltd ADR](https://www.valueray.com/images/drawdown_chart/TEVA.NYSE_drawdown.png)
Overall Trend and Yearly Seasonality
![Drawdown / Underwater Chart for TEVA - Teva Pharma Industries Ltd ADR](https://www.valueray.com/images/chart/TEVA.NYSE_seasonality.png)
TEVA Stock Overview
Market Cap in USD | 19,051m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC SubIndustry | Pharmaceuticals |
TER | 0.00% |
IPO / Inception | 1990-03-26 |
TEVA Stock Ratings
Growth 5y | 43.1 |
Fundamental | -1.12 |
Dividend | 11.5 |
Rel. Performance vs Sector | 2.75 |
Analysts | 3.92/5 |
Fair Price Momentum | 18.43 USD |
Fair Price DCF | 27.30 USD |
TEVA Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 73.0% |
TEVA Growth Ratios
Growth 12m | 99.77% |
Growth Correlation 12m | 75% |
Growth Correlation 3m | 30% |
CAGR 5y | 16.79% |
CAGR/Mean DD 5y | 0.70 |
Sharpe Ratio 12m | 2.63 |
Alpha vs SP500 12m | 75.67 |
Beta vs SP500 5y weekly | 1.21 |
ValueRay RSI | 39.24 |
Volatility GJR Garch 1y | 38.27% |
Price / SMA 50 | 2.15% |
Price / SMA 200 | 32.15% |
Current Volume | 9088.5k |
Average Volume 20d | 9052k |
External Links for TEVA Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of July 27, 2024, the stock is trading at USD 17.10 with a total of 9,088,470 shares traded.
Over the past week, the price has changed by +1.73%, over one month by +5.23%, over three months by +23.82% and over the past year by +103.57%.
According to ValueRays Forecast Model, TEVA Teva Pharma Industries Ltd ADR will be worth about 19.9 in July 2025. The stock is currently trading at 17.10. This means that the stock has a potential upside of +16.61%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 19 | 11.1 |
Analysts Target Price | 10.6 | -38.2 |
ValueRay Target Price | 19.9 | 16.6 |